Global Wholehealth Partners Corp. is Preparing Itself to be the First Fully Green Medical Device Supplier, by Using Biodegradable Plastics for All Cassettes, Midstream, Urine Cups and Other Testing Devices. A Biodegradable Material for Producing a Medical Device is the Next Step in a Clearer Environment
Global WholeHealth Partners Corp. (OTC:GWHP) announces today that it has signed an agreement with Charles Strongo for the right to sell and manufacture Biodegradable plastic for medical devices. Provisional Patent number 63/054,139, as mentioned in 8k filing on 01/21/2021.
Global WholeHealth Partners Corp. (OTC:GWHP) understands the growth needed in the in-vitro diagnostic segment and the need for more rapid tests, and at the same time understands that we all need to GO GREEN. Mr. Strongo took that challenge and created a proper mix of plant based material which is 100% biodegradable, to make a plastic that is biodegradable to help the medical industry GO GREEN.
Global knows that tens of millions of plastic medical devices are used every month in the US alone and hundreds of millions throughout the world. Just in the US alone, Healthcare facilities across America generate around 14,000 tons (28,000,000 lbs.) of waste per day. Up to 25% of this is made up of plastic products.
Global WholeHealth Partners Corp., a multinational supplier of over 70+ with 56 products FDA approved and several approved for export only including Dengue, Ebola, Zika, and Malaria also offering one of the largest lines of tests for CoViD19 SARS2, is prepared to help in the fight against CoViD19 SARS2. With the pandemic out of control in the United States, the nation's coronavirus testing system is starting to strain again.
About 30 million Covid-19 tests are given every month, according to estimates from The Atlantic magazine’s Covid Tracking Project. But studies have found that the U.S. would need millions more —193 million a month, according to one report — to be effective.
The USA has the largest number of Covid-19 cases in the world and there is concern that this next wave of infections will be worse than the previous. Global WholeHealth Partners, Corp. is confident that its Covid-19 Rapid Test can make a difference through assisting companies, staff, and public places where transmission may occur with a reliable, accurate, and fast Rapid Test
Global Wholehealth Partners Corp. provides cutting edge technology using In-vitro Diagnostic (IVD) Real-Time PCR Machines for detection of SARS-CoV-2 IgM/IgG antibodies in human serum, plasma, or whole blood. It has led the fight against vector borne terminal diseases such as Ebola, ZIKA, Dengue, Malaria, Influenza and Tuberculosis, Corona Viruses, and among other vector borne diseases. The company was founded on March 7, 2013 and is headquartered in San Clemente, CA.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time
This press release contains "forward-looking statements.” Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.